Response rates of taxane rechallenge in metastatic breast cancer patients, previously treated with adjuvant taxanes.

被引：1
|
作者：
Oguz, Arzu
Babacan, Taner
Dizdar, Omer
Kucukoztas, Nadire
Rahatli, Samed
Keskin, Gul Sema Yildiran
Altundag, Ozden
Altundag, Kadri
机构：
[1] Baskent Univ, Dept Med Oncol, TR-06490 Ankara, Turkey
[2] Hacettepe Univ, Inst Oncol, Dept Med Oncol, Ankara, Turkey
[3] Baskent Univ Hosp, Ankara, Turkey
[4] Baskent Univ, Sch Med, TR-06490 Ankara, Turkey
[5] Baskent Univ, Fac Med, TR-06490 Ankara, Turkey
[6] Hacettepe Univ, Inst Canc, Dept Med Oncol, Ankara, Turkey
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 15期
关键词：
D O I：
10.1200/jco.2014.32.15_suppl.1073
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1073
引用
收藏
页数：1
相关论文
共 50 条
  • [21] A multicentric phase II study with vinorelbine and protracted fluorouracil infusion for advanced breast cancer patients previously treated with anthracyclines and/or taxanes. Is salvage chemotherapy for metastatic breast cancer always effective and well tolerated?
    Kanaev, S
    Novikov, S
    Jukova, L
    EUROPEAN JOURNAL OF CANCER, 2002, 38 : S70 - S70
  • [22] Predictors of chemotherapy-induced peripheral neuropathy among breast cancer patients treated with taxanes.
    Candelario, Nellowe
    Wongrakpanich, Supakanya
    Morginstin, Mark S.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (28)
  • [23] A phase I study of vinflunine in combination with capecitabine in patients with metastatic breast cancer previously treated with anthracyclines and taxanes
    Campone, M.
    Isambert, N.
    Bourbouloux, E.
    Roche, H.
    Bonneterre, J.
    Milano, G.
    Fumoleau, P.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2012, 69 (04) : 871 - 879
  • [24] A phase I/II study of bortezomib and capecitabine in patients with metastatic breast cancer previously treated with taxanes and/or anthracyclines
    Schmid, P.
    Kuehnhardt, D.
    Kiewe, P.
    Lehenbauer-Dehm, S.
    Schippinger, W.
    Greil, R.
    Lange, W.
    Preiss, J.
    Niederle, N.
    Brossart, P.
    Freier, W.
    Kuemmel, S.
    de Velde, H. Van
    Regierer, A.
    Possinger, K.
    ANNALS OF ONCOLOGY, 2008, 19 (05) : 871 - 876
  • [25] Population Pharmacometric Analyses of Eribulin in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With Anthracyclines and Taxanes
    Majid, Oneeb
    Gupta, Anubha
    Reyderman, Larisa
    Olivo, Martin
    Hussein, Ziad
    JOURNAL OF CLINICAL PHARMACOLOGY, 2014, 54 (10): : 1134 - 1143
  • [26] Phase I trial of bortezomib and capecitabine in patients with metastatic breast cancer previously treated with taxanes and/or anthracyclines.
    Possinger, K
    Schippinger, W
    Kiewe, P
    Lange, W
    Preiss, J
    Niederle, N
    Brossart, P
    Papke, J
    Freier, W
    de Velde, HV
    Schmid, P
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 66S - 66S
  • [27] A phase I study of vinflunine in combination with capecitabine in patients with metastatic breast cancer previously treated with anthracyclines and taxanes
    M. Campone
    N. Isambert
    E. Bourbouloux
    H. Roché
    J. Bonneterre
    G. Milano
    P. Fumoleau
    Cancer Chemotherapy and Pharmacology, 2012, 69 : 871 - 879
  • [28] Re-Challenging Taxanes in Recurrent Breast Cancer in Patients Treated with (Neo-)Adjuvant Taxane-Based Therapy
    Guo, Xinrong
    Loibl, Sibylle
    Untch, Michael
    Moebus, Volker
    Schwedler, Kathrin
    Fasching, Peter A.
    Barinoff, Jana
    Holms, Frank
    Thomssen, Christoph
    Zahm, Dirk M.
    Kreienberg, Rolf
    Hauschild, Maik
    Eidtmann, Holger
    Tauchert, Sascha
    Mehta, Keyur
    von Minckwitz, Gunter
    BREAST CARE, 2011, 6 (04) : 279 - 283
  • [29] Efficacy and safety of eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with anthracycline/taxanes
    Chen, Lan
    Yan, Xi
    Luo, Ting
    Tian, Tinglun
    He, Ping
    Zhong, Xiaorong
    CANCER MEDICINE, 2024, 13 (10):
  • [30] Chemotherapy-induced amenorrhea from adjuvant breast cancer treatment: The effect of taxanes.
    Mintzer, DM
    Davis, AL
    Klitus, M
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 48S - 48S
12345